Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency

Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety,... Opinion EDITORIAL Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency Mark D. Huffman, MD, MPH; Gbenga Ogedegbe, MD, MPH; Marc Jaffe, MD In this issue of JAMA, Webster and colleagues report the re- (15.6% vs 9.4%, respectively), modeled estimates from TRIUMPH that accounted for baseline serum potassium lev- sults of the Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) pragmatic els suggest that the effect of the triple combination pill on po- randomized clinical trial that evaluated the efficacy of a low- tassium was small (adjusted difference in serum potassium dose combination pill con- level, −0.22 mmol/L [95% CI, −0.29 to −0.15 mmol/L]). Fur- taining 20 mg of telmisartan, thermore, there appears to be no effect on serum creatinine Related article page 566 2.5 mg of amlodipine, and level (adjusted difference in serum creatinine level, 0.04 mg/dL 12.5 mg of chlorthalidone compared with usual care among 700 [95% CI, −0.06 to 0.14 mg/dL]). Even though larger trials are adults with hypertension in Sri Lanka. The primary outcome needed to evaluate longer-term safety in more diverse popu- was the proportion of patients whose blood pressure (BP) lations, the initial safety signal appears http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency

JAMA , Volume 320 (6) – Aug 14, 2018

Loading next page...
 
/lp/american-medical-association/low-dose-combination-blood-pressure-pharmacotherapy-to-improve-oLm8y0Po4S
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2018.10649
pmid
30120460
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Low-Dose Combination Blood Pressure Pharmacotherapy to Improve Treatment Effectiveness, Safety, and Efficiency Mark D. Huffman, MD, MPH; Gbenga Ogedegbe, MD, MPH; Marc Jaffe, MD In this issue of JAMA, Webster and colleagues report the re- (15.6% vs 9.4%, respectively), modeled estimates from TRIUMPH that accounted for baseline serum potassium lev- sults of the Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) pragmatic els suggest that the effect of the triple combination pill on po- randomized clinical trial that evaluated the efficacy of a low- tassium was small (adjusted difference in serum potassium dose combination pill con- level, −0.22 mmol/L [95% CI, −0.29 to −0.15 mmol/L]). Fur- taining 20 mg of telmisartan, thermore, there appears to be no effect on serum creatinine Related article page 566 2.5 mg of amlodipine, and level (adjusted difference in serum creatinine level, 0.04 mg/dL 12.5 mg of chlorthalidone compared with usual care among 700 [95% CI, −0.06 to 0.14 mg/dL]). Even though larger trials are adults with hypertension in Sri Lanka. The primary outcome needed to evaluate longer-term safety in more diverse popu- was the proportion of patients whose blood pressure (BP) lations, the initial safety signal appears

Journal

JAMAAmerican Medical Association

Published: Aug 14, 2018

References